PTC Stock Recent News
PTC LATEST HEADLINES
New cloud-native supply chain offering delivers supply chain risk insights directly into product lifecycle management Arena SCI proactively monitors component risks and recommends alternative options to prevent sourcing interruptions Arena SCI builds on longstanding supplier collaboration capabilities with new features powered by Arena AI BOSTON , June 24, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced the release of its Arena ® product lifecycle management (PLM) and quality management system (QMS) solution's new Supply Chain Intelligence (SCI) offering. The Arena SCI™ offering continuously checks for emerging risks from evolving supply chain conditions and eliminates the need for disconnected supply chain tools by embedding real-time, AI-driven component monitoring and risk mitigation insight directly into product development workflows.
NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
WARREN, N.J. , June 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 16, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,725 shares of its common stock and 27,790 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 34 new employees.
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PTC debuts the first cloud-native MBD in Onshape, aiming to cut 2D drawing reliance and streamline product development.
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PTC's diversified software suite and high-margin recurring revenue model drive solid fundamentals, despite capability competition from Autodesk and Dassault. Operating margins are expanding, now at ~35%, and PTC trades at a valuation discount versus peers, offering attractive upside if ARR growth reaccelerates. Strategic SaaS pivots and targeted R&D deliver superior margin efficiency and innovation, positioning PTC well for long-term cloud-native trends in industrials.
NEW YORK , June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.